Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Perla Lansang"'
Autor:
Ronald Vender, MD, Irina Turchin, MD, Perla Lansang, MD, Vimal H. Prajapati, MD, Mark Legault, PhD, Maxime Barakat, MD, PhD, MBA, Jensen Yeung, MD
Publikováno v:
JAAD International, Vol 8, Iss , Pp 60-63 (2022)
Externí odkaz:
https://doaj.org/article/a53ddb810c5f4625922358a67799b58b
Publikováno v:
SAGE Open Medical Case Reports, Vol 11 (2023)
A patient presented to clinic with atopic dermatitis that had been previously unresponsive to multiple topical and systemic therapies. They were successfully treated with a combination of tralokinumab and upadacitinib, showing significant improvement
Externí odkaz:
https://doaj.org/article/830b213bd2d04ae39f8ed559394346c1
Publikováno v:
JAAD Case Reports, Vol 33, Iss , Pp 54-55 (2023)
Externí odkaz:
https://doaj.org/article/29e4dbce95b64536930bb136815828a4
Autor:
Michelle Le, Melissa Berman-Rosa, Feras M. Ghazawi, Marc Bourcier, Loretta Fiorillo, Melinda Gooderham, Lyn Guenther, Sameh Hanna, H. Chih-Ho Hong, Ian Landells, Perla Lansang, Danielle Marcoux, Marni C. Wiseman, Jensen Yeung, Charles Lynde, Ivan V. Litvinov
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Background: Atopic dermatitis is a chronic, relapsing and remitting disease that can be difficult to treat despite a recently approved biologic therapy targeting IL-4/IL-13 receptor. Oral janus kinase inhibitors (JAKi) represent a novel therapeutic c
Externí odkaz:
https://doaj.org/article/f52d9dc4eec44b8d8da97803c35cd761
Publikováno v:
SAGE Open Medical Case Reports, Vol 6 (2018)
Eosinophilia, both peripheral and in cutaneous tissue, is not a typical finding in mycosis fungoides; in fact, when faced with a lymphoeosinophilic infiltrate, mycosis fungoides is often not part of initial differential considerations. However, eosin
Externí odkaz:
https://doaj.org/article/544dd137e68e4831a994d28bfb7421b5
Autor:
Jensen Yeung, Melinda J. Gooderham, H. Chih-Ho Hong, Charles Lynde, Vimal H. Prajapati, Perla Lansang, Irina Turchin, Marni Wiseman, Carolyn Jack, Michele Ramien, Kerri Purdy, Parbeer Grewal
Publikováno v:
Journal of the American Academy of Dermatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d28cdc83c56fd377a4d1c63b8c50563
https://doi.org/10.1016/j.jaad.2023.01.053
https://doi.org/10.1016/j.jaad.2023.01.053
Autor:
Melinda Gooderham, Neil H. Shear, M Perla Lansang, Jennifer Beecker, Carolyn Jack, Kim A. Papp, Charles Lynde, Irina Turchin, Chih-Ho Hong, David N. Adam, Marissa Joseph, Robert Bissonnette
Publikováno v:
Dermatology and Therapy
Introduction Dupilumab is approved to treat moderate-to-severe atopic dermatitis (AD) in several countries in patients as young as 6 years of age. Since its approval, practical issues related to the use of dupilumab for AD have arisen, with particula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71806fb2fe5e175479eef49ab3aa4926
https://doi.org/10.1007/s13555-021-00586-w
https://doi.org/10.1007/s13555-021-00586-w
Autor:
Brian D. Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, Asfandyar Mufti, Alim R. Devani, Melinda J. Gooderham, Chih-Ho Hong, Vipul Jain, Perla Lansang, Ronald Vender, Jensen Yeung, Vimal H. Prajapati
Publikováno v:
Journal of Dermatological Treatment. 33:2692-2694
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55b88786d34d20aa9ef532507c55b257
https://doi.org/10.1080/09546634.2022.2036673
https://doi.org/10.1080/09546634.2022.2036673
Publikováno v:
Journal of Cutaneous Medicine and Surgery. 27:177-178
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25e53d420af741683f699d3864c17b51
https://doi.org/10.1177/12034754231152223
https://doi.org/10.1177/12034754231152223
Autor:
Jensen Yeung, Marc Bourcier, Melinda J. Gooderham, Parbeer Grewal, Chih‐Ho Hong, Perla Lansang, Charles Lynde, Catherine Maari, Vimal H. Prajapati, Irina Turchin, Ron Vender
Publikováno v:
Dermatologic therapyREFERENCES. 35(10)
Treat-to-target (T2T) recommendations for the use of systemic therapies (including biologics) in patients with moderate-to-severe plaque psoriasis have been published by a few groups of experts worldwide. However, there remains considerable variabili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2ccdda463986a73c12215dd9e2f332b
https://pubmed.ncbi.nlm.nih.gov/35988045
https://pubmed.ncbi.nlm.nih.gov/35988045